References
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633. DOI:10.1016/j.juro.2018.05.004
- Weider JA. Pocket Guide Urology. 6th ed. United States. J Weider Medical. 2021;2:509–533.
- Belew D, Klaassen Z, Lewis RW. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. SMR. 2015;3(1):11–23.
- Virag R. Intracavernous injection of papaverine for erectile failure. Lancet. 1982;2(8304):938. DOI:10.1016/S0140-6736(82)90910-2
- Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry. 1983;143:332–337.
- Smith WB, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013;67(8):768–780. DOI:10.1111/ijcp.12074
- Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am. 2007;36(2):465–479.
- European Association of Urology. EAU guidelines on male infertility - uroweb. Available at: https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/male-infertility. Accessed Dec 12, 2022.
- Daily Med U.S National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e8b8ec8d-1318-43e4-a182-446e9f9579de&type=display. Accessed Dec. 19, 2022.
- Prescribers’ digital reference. https://www.pdr.net/drug-summary/Papaverine-Hydrochloride-papaverine-hydrochloride-24173. Accessed Dec. 8, 2022.
- Kasperek R, Zimmer Ł, Jawień W, et al. Pharmacokinetics of diclofenac sodium and papaverine hydrochloride after oral administration of tablets to rabbits. Acta Pol Pharm. 2015;72(3):527–538.
- Ritschel WA, Hammer GV. Pharmacokinetics of papaverine in man. Int J Clin Pharmacol Biopharm. 1977;15(5):227–228.
- National Center for Biotechnology Information. PubChem compound summary for CID 5280723, Alprostadil. https://pubchem.ncbi.nlm.nih.gov/compound/5280723. Accessed Dec. 8, 2022.
- Daily Med U.S National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98. Accessed Dec. 8, 2022.
- Food and Drug Administration. (n.d.). Caverject. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020379s032lbl.pdf. Accessed Mar. 20, 2022.
- Sooriyamoorthy T, Leslie SW StatPearls. Erectile Dysfunction. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562253/. Accessed Dec. 8, 2022.
- Jain A, Iqbal OA StatPearls. Alprostadil. Available at: https://www.ncbi.nlm.nih.gov/books/NBK542217/. Accessed Dec. 8, 2022.
- Daily Med U.S National Library of Medicine. Papaverine Hydrochloride. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e76839f-82eb-42a8-abc2-e7fbc533082d. Accessed Dec. 8, 2022.
- National Center for Biotechnology Information. PubChem compound summary for CID 5775, Phentolamine. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/5775. Accessed Dec. 9, 2022.
- National Center for Biotechnology Information. PubChem compound summary for CID 16132300, Aviptadil. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/16132300. Accessed Dec. 9, 2022.
- Choi YD, Chung WS, Choi HK. The action mechanism of relaxation effect of atropine on the isolated rabbit corpus cavernosum. J Urol. 1999;161(6):1976–1979.
- der Meer MJ V, Hundt HK, Müller FO. The metabolism of atropine in man. J Pharm Pharmacol. 1986;38(10):781–784.
- Burnett AL, Ramasamy R. Evaluation and management of erectile dysfunction . In: Partin AW, Dmochowski RR, Kavoussi KR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA:Elsevier; chap 69. 2021.
- Lea AP, Bryson HM, Balfour JA. Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging. 1996;8(1):56–74. DOI:10.2165/00002512-199608010-00009
- Moreland RB, Kim N, Nehra A, et al. Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res. 2003;15(5):362–368.
- National Center for Biotechnology Information. PubChem compound summary for CID 6084, Papaverine hydrochloride. https://pubchem.ncbi.nlm.nih.gov/compound/papaverine-hydrochloride. Accessed Dec. 8, 2022.
- Montorsi F, Guazzoni G, Bergamaschi F, et al. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J Urol. 1993;149(5 Pt 2):1291–1295.
- Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008;102(8):933–937.
- Le TV, Tsambarlis P, Hellstrom WJG. Pharmacodynamics of the agents used for the treatment of erectile dysfunction. Expert Opin Drug Metab Toxicol. 2019;15(2):121–131.
- Sogari PR, Telöken C, Souto CA. Atropine role in the pharmacological erection test: study of 228 patients. J Urol. 1997;158(5):1760–1763.
- Porst H, Buvat J, Meuleman E, et al. Intracavernous Alprostadil Alfadex–an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res. 1998;10(4):225–231.
- Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130–171. DOI:10.1111/jsm.12023
- Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334(14):873–877.
- Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155(3):802–815.
- Yasumoto R, Asakawa M, Kawashima H, et al. Intracavernous injection of vasoactive drugs for treating erectile impotence. Hinyokika Kiyo. 1988;34(2):301–304.
- Goldstein I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res. 2000;12(S1):75–80.
- Sironi G, Colombo D, Poggesi E, et al. Effects of intracavernous administration of selective antagonists of alpha(1)-adrenoceptor subtypes on erection in anesthetized rats and dogs. J Pharmacol Exp Ther. 2000;292(3):974–981.
- Juenemann KP, Lue TF, Fournier GR, et al. Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol. 1986;136(1 Part 1):158–161. DOI:10.1016/S0022-5347(17)44763-X
- Blum MD, Bahnson RR, Porter TN, et al. Effect of local alpha-adrenergic blockade on human penile erection. J Urol. 1985;134(3):479–481. DOI:10.1016/S0022-5347(17)47248-X
- Gerstenberg TC, Metz P, Ottesen B, et al. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol. 1992;147(5):1277–1279. DOI:10.1016/S0022-5347(17)37541-9
- Shah PJ, Dinsmore W, Oakes RA, et al. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin. 2007;23(10):2577–2583.
- Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol. 1985;133(1):39–41.
- Bernie HL, Segal R, Le B, et al. An empirical vs risk-based approach algorithm to intracavernosal injection therapy: a prospective study. J Sex Med. 2017;5(1):e31–6. DOI:10.1016/j.esxm.2016.08.001
- Kulaksizoglu H, Hakim LS, Nehra A, et al. Comparison of alprostadil sterile powder (Caverject®) with trimix. Nomogram and patient satisfaction. J Urol. 1997;157(Suppl 4):180.
- Shenfeld O, Hanani J, Shalhav A, et al. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol. 1995;154(3):1017–1019. DOI:10.1016/S0022-5347(01)66964-7
- Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991;146(6):1564–1565.
- Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the fourth international consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465–488. DOI:10.1016/j.jsxm.2016.01.016
- Baniel J, Israilov S, Engelstein D. Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs. Urol J. 2000;56(4):647–652.
- Food and Drug Administration. Caverject® alprostadil for injection for Intracavernosal Use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020379s028lbl.pdf. Accessed Dec. 9, 2022.
- Food and Drug Administration. Edex (alprostadil for injection) for Intracavernous Use Only. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020649s023lbl.pdf. Accessed Dec. 9, 2022.
- Moemen MN, Hamed HA, Kamel II, et al. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. Int J Impot Res. 2004;16(2):143–145. DOI:10.1038/sj.ijir.3901194
- Brown SL, Haas CA, Koehler M, et al. Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Urol J. 1998;52(5):844–847. DOI:10.1016/S0090-4295(98)00290-8
- Sandhu D, Curless E, Dean J, et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res. 1999;11(2):91–97. DOI:10.1038/sj.ijir.3900388
- Shamloul R, Atteya A, Elnashaar A, et al. Intracavernous Sodium Nitroprusside (SNP) versus Papaverine/Phentolamine in Erectile Dysfunction: a Comparative Study of Short-Term Efficacy and Side-Effects. J Sex Med. 2005;2(1):117–120. DOI:10.1111/j.1743-6109.2005.20121.x
- Albaugh JA. Intracavernosal Injection Algorithm. Urol Nurs. 2006;26(6):449–453.
- Levine SB, Althor SE, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol. 1989;141(1):54–58. DOI:10.1016/S0022-5347(17)40585-4
- Israilov S, Baniel J, Shmueli J, et al. Treatment program for erectile dysfunction in patients with cardiovascular diseases. Am J Cardiol. 2004;93(6):689–693. DOI:10.1016/j.amjcard.2003.11.049
- Sung HH, Ahn JS, Kim JJ, et al. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology. 2014;2(1):45–50. DOI:10.1111/j.2047-2927.2013.00155.x
- Mirzaei M, Bagherinasabsarab M, Pakmanesh H, et al. The effect of intracavernosal injection of stem cell in the treatment of erectile dysfunction in diabetic patients: a randomized single-blinded clinical trial. Urol J. 2021;18(6):675–681. DOI:10.22037/uj.v18i.6503